Published in Br J Dermatol on February 01, 2007
Skin changes following organ transplantation: an interdisciplinary challenge. Dtsch Arztebl Int (2014) 1.39
Management of high-risk cutaneous squamous cell carcinoma. J Clin Aesthet Dermatol (2010) 1.30
Recent advances in the prevention and treatment of skin cancer using photodynamic therapy. Expert Rev Anticancer Ther (2010) 1.21
Photodynamic therapy in dermatology: a review. Lasers Med Sci (2009) 1.09
Review of photodynamic therapy in actinic keratosis and basal cell carcinoma. Ther Clin Risk Manag (2008) 1.08
Biomodulatory approaches to photodynamic therapy for solid tumors. Cancer Lett (2012) 1.08
Current evidence and applications of photodynamic therapy in dermatology. Clin Cosmet Investig Dermatol (2014) 0.96
Nonsurgical innovations in the treatment of nonmelanoma skin cancer. J Clin Aesthet Dermatol (2010) 0.89
Basal cell carcinoma treated successfully with combined CO2 laser and photodynamic therapy in a renal transplant patient: a case report. Cases J (2009) 0.78
Beyond the margins: real-time detection of cancer using targeted fluorophores. Nat Rev Clin Oncol (2017) 0.78
Oral azathioprine leads to higher incorporation of 6-thioguanine in DNA of skin than liver: the protective role of the Keap1/Nrf2/ARE pathway. Cancer Prev Res (Phila) (2011) 0.77
Aminolevulinic Acid-photodynamic therapy of Basal cell carcinoma and factors affecting the response to treatment: a clinical trial. Indian J Dermatol (2013) 0.76
Use of photodynamic therapy for treatment of actinic keratoses in organ transplant recipients. Biomed Res Int (2012) 0.76
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Skin cancers after organ transplantation. N Engl J Med (2003) 6.65
Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol (1999) 3.19
Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science (2005) 2.31
Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation (1990) 2.07
The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation (1996) 1.75
Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol (2002) 1.54
Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. Br J Cancer (1994) 1.40
The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. Cancer Res (1996) 1.35
Human papilloma virus infection and skin cancer in renal allograft recipients. Lancet (1989) 1.34
5-aminolevulinic acid, but not 5-aminolevulinic acid esters, is transported into adenocarcinoma cells by system BETA transporters. Photochem Photobiol (2000) 1.20
Fluorouracil: mechanism of action in human skin and actinic keratoses. I. Effect on DNA synthesis in vivo. Arch Dermatol (1970) 1.19
Photodynamic therapy-mediated immune response against subcutaneous mouse tumors. Cancer Res (1999) 1.19
Prodrugs of 5-aminolevulinic acid for photodynamic therapy. Photochem Photobiol (1996) 1.19
Comparison of red and green light in the treatment of Bowen's disease by photodynamic therapy. Br J Dermatol (2000) 1.17
DNA single-strand breaks and sister chromatid exchanges induced by treatment with hematoporphyrin and light or by x-rays in human NHIK 3025 cells. Cancer Res (1980) 1.15
Skin tumours posttransplantation: a retrospective analysis of 28 years' experience at a single centre. Transplant Proc (1997) 1.14
Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol (2002) 1.11
Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study. J Am Acad Dermatol (2002) 1.11
Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res (2002) 1.08
5-Aminolevulinic acid and its derivatives: physical chemical properties and protoporphyrin IX formation in cultured cells. J Photochem Photobiol B (2000) 1.03
Incidence and treatment of neoplasia after transplantation. J Heart Lung Transplant (1994) 1.02
Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation (2004) 1.02
A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat (2003) 1.02
Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol (2003) 1.01
Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Photochem Photobiol B (2001) 0.99
Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial. Arch Dermatol (2005) 0.99
Preferential relative porphyrin enrichment in solar keratoses upon topical application of delta-aminolevulinic acid methylester. Photochem Photobiol (1998) 0.99
Bowen's disease, solar keratoses and superficial basal cell carcinomas treated by photodynamic therapy using a large-field incoherent light source. Br J Dermatol (2001) 0.94
Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. Br J Dermatol (2003) 0.94
A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol (1999) 0.91
Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study. Dermatology (1996) 0.90
Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br J Dermatol (1996) 0.87
Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: results of a randomized-controlled trial. J Invest Dermatol (2006) 0.86
Skin cancers after transplantation. Nephrol Dial Transplant (2003) 0.86
DNA alkylation by 4,5-dioxovaleric acid, the final oxidation product of 5-aminolevulinic acid. Chem Res Toxicol (1998) 0.86
A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol (2004) 0.85
Genotoxic potential of porphyrin type photosensitizers with particular emphasis on 5-aminolevulinic acid: implications for clinical photodynamic therapy. Free Radic Biol Med (2000) 0.84
PDT as a cytotoxic agent and biological response modifier: Implications for cancer prevention and treatment in immunosuppressed and immunocompetent patients. J Invest Dermatol (2006) 0.84
Weekly pulse dosing: effective and comfortable topical 5-fluorouracil treatment of multiple facial actinic keratoses. J Am Acad Dermatol (1991) 0.82
Metvix (PhotoCure). Curr Opin Investig Drugs (2002) 0.81
Topical treatment of Bowen's disease with 5-Fluorouracil. J Cutan Med Surg (2002) 0.80
Photodynamic therapy of virus-associated epithelial tumours of the face in organ transplant recipients. J Cancer Res Clin Oncol (2004) 0.79
Multiple large-surface photodynamic therapy sessions with topical or systemic aminolevulinic acid and blue light in UV-exposed hairless mice. J Cutan Med Surg (2004) 0.78
Photodynamic therapy with topical delta-aminolevulinic acid delays UV photocarcinogenesis in hairless mice. Photochem Photobiol (1997) 0.78
Connexin 26 mutations in hereditary non-syndromic sensorineural deafness. Nature (1997) 6.89
Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature (1998) 6.16
Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. Hum Mol Genet (2000) 3.39
Induction of a DNA glycosylase for N-methylated purines is part of the adaptive response to alkylating agents. Nature (1982) 3.11
Inducible repair of O-alkylated DNA pyrimidines in Escherichia coli. EMBO J (1984) 2.77
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet (2000) 2.69
Overdiagnosis in screening: is the increase in breast cancer incidence rates a cause for concern? J Med Screen (2004) 2.62
Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature (1993) 2.57
A mutation in the conserved helix termination peptide of keratin 5 in hereditary skin blistering. Nature (1992) 2.49
Sunscreens, suntans, and skin cancer. BMJ (1996) 2.34
Mismatch correction at O6-methylguanine residues in E. coli DNA. Nature (1982) 2.33
Escherichia coli mutants deficient in 3-methyladenine-DNA glycosylase. J Mol Biol (1980) 2.32
Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J Natl Cancer Inst (1996) 2.28
The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor. J Cell Biol (1989) 2.27
Keratin antigens in differentiating skin. Ann N Y Acad Sci (1985) 2.10
High levels of type VII collagen expression in recessive dystrophic epidermolysis bullosa cutaneous squamous cell carcinoma keratinocytes increases PI3K and MAPK signalling, cell migration and invasion. Br J Dermatol (2014) 2.09
Antibody markers of basal cells in complex epithelia. J Cell Sci (1990) 2.08
Keratin expression in human mammary epithelial cells cultured from normal and malignant tissue: relation to in vivo phenotypes and influence of medium. J Cell Sci (1989) 2.07
Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol (2000) 2.03
Linkage of an American pedigree with palmoplantar keratoderma and malignancy (palmoplantar ectodermal dysplasia type III) to 17q24. Literature survey and proposed updated classification of the keratodermas. Arch Dermatol (1996) 2.00
Basal cell-specific and hyperproliferation-related keratins in human breast cancer. Am J Pathol (1991) 1.88
Expression of simple epithelial keratins 8 and 18 in epidermal neoplasia. J Invest Dermatol (1991) 1.87
Enzymatic excision of free hypoxanthine from polydeoxynucleotides and DNA containing deoxyinosine monophosphate residues. J Biol Chem (1978) 1.84
A case-control study to estimate the impact on breast cancer death of the breast screening programme in Wales. J Med Screen (2004) 1.81
p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet (1998) 1.79
Plectin deficiency results in muscular dystrophy with epidermolysis bullosa. Nat Genet (1996) 1.78
Loss of plectin causes epidermolysis bullosa with muscular dystrophy: cDNA cloning and genomic organization. Genes Dev (1996) 1.75
Altered laminin 5 expression due to mutations in the gene encoding the beta 3 chain (LAMB3) in generalized atrophic benign epidermolysis bullosa. J Invest Dermatol (1995) 1.69
Mutations in the plakophilin 1 gene result in ectodermal dysplasia/skin fragility syndrome. Nat Genet (1997) 1.68
Melanoma in organ transplant recipients: clinicopathological features and outcome in 100 cases. Am J Transplant (2008) 1.65
Idiopathic scrotal calcinosis is idiopathic. J Am Acad Dermatol (1991) 1.64
DNA excision repair pathways. Curr Opin Genet Dev (1997) 1.64
Binding of integrin alpha6beta4 to plectin prevents plectin association with F-actin but does not interfere with intermediate filament binding. J Cell Biol (1999) 1.64
Loss of desmoplakin isoform I causes early onset cardiomyopathy and heart failure in a Naxos-like syndrome. J Med Genet (2006) 1.64
DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines. Cancer Res (1995) 1.64
Keratin 19: predicted amino acid sequence and broad tissue distribution suggest it evolved from keratinocyte keratins. J Invest Dermatol (1989) 1.61
Hypoxanthine in deoxyribonucleic acid: generation by heat-induced hydrolysis of adenine residues and release in free form by a deoxyribonucleic acid glycosylase from calf thymus. Biochemistry (1980) 1.59
Psoriasis: maintenance of an intact monolayer basal cell differentiation compartment in spite of hyperproliferation. Br J Dermatol (1985) 1.58
Aberrant integrin expression during epidermal wound healing and in psoriatic epidermis. J Clin Invest (1992) 1.58
Blue calls--time for a change? Emerg Med J (2001) 1.55
Intraepidermal type VII collagen. Evidence for abnormal intracytoplasmic processing of a major basement membrane protein in rare patients with dominant and possibly localized recessive forms of dystrophic epidermolysis bullosa. J Am Acad Dermatol (1990) 1.54
Distribution of cytokeratin polypeptides in human transitional cell carcinomas, with special emphasis on changing expression patterns during tumor progression. Am J Pathol (1990) 1.53
Haploinsufficiency of desmoplakin causes a striate subtype of palmoplantar keratoderma. Hum Mol Genet (1999) 1.52
O6-Methylguanine-DNA methyltransferase of human lymphoid cells: structural and kinetic properties and absence in repair-deficient cells. Cancer Res (1983) 1.52
Specific types of human papillomavirus found in benign proliferations and carcinomas of the skin in immunosuppressed patients. Cancer Res (1994) 1.51
Site-specific mutagenesis in vivo by single methylated or deaminated purine bases. Mutat Res (1986) 1.51
Guidelines for the management of actinic keratoses. Br J Dermatol (2007) 1.49
Connexin mutations associated with palmoplantar keratoderma and profound deafness in a single family. Eur J Hum Genet (2000) 1.48
A functional "knockout" of human keratin 14. Genes Dev (1994) 1.48
Genetic steps in colorectal cancer. Nat Genet (1994) 1.48
Detection of basement membrane components and basal cell keratin 14 in noninvasive and invasive carcinomas of the breast. Am J Pathol (1989) 1.46
Immunohistochemical analysis of burn depth. J Burn Care Rehabil (1999) 1.46
Degenerate and nested PCR: a highly sensitive and specific method for detection of human papillomavirus infection in cutaneous warts. J Clin Microbiol (1999) 1.46
HLA-DR4 may determine expression of actinic prurigo in British patients. J Invest Dermatol (1996) 1.44
DNA mismatch binding and incision at modified guanine bases by extracts of mammalian cells: implications for tolerance to DNA methylation damage. Biochemistry (1994) 1.43
cDNA cloning and chromosomal assignment of the human O6-methylguanine-DNA methyltransferase. cDNA expression in Escherichia coli and gene expression in human cells. J Biol Chem (1990) 1.43
Localization of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-q43. Am J Hum Genet (2001) 1.42
Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet (1992) 1.41
Immortalisation of human urothelial cells. Urol Res (1995) 1.38
Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts. Nucleic Acids Res (1997) 1.38
A novel human type II cytokeratin, K6hf, specifically expressed in the companion layer of the hair follicle. J Invest Dermatol (1998) 1.37
Fumarate hydratase mutations and predisposition to cutaneous leiomyomas, uterine leiomyomas and renal cancer. Br J Dermatol (2005) 1.37
Interleukin 6 is a prognostic indicator of outcome in severe intra-abdominal sepsis. Br J Surg (1994) 1.36
N-terminal deletion in a desmosomal cadherin causes the autosomal dominant skin disease striate palmoplantar keratoderma. Hum Mol Genet (1999) 1.35
Potential applications of anti-keratin antibodies in oral diagnosis. J Oral Pathol (1987) 1.33
Surgical treatment of the spontaneous spinal epidural abscess. Surg Neurol (1992) 1.32
Missense mutations in keratin 17 cause either pachyonychia congenita type 2 or a phenotype resembling steatocystoma multiplex. J Invest Dermatol (1997) 1.32
Parathyroid hormone related protein and skeletal morbidity in breast cancer. Eur J Cancer (1992) 1.31
Repair of O-alkylpyrimidines in mammalian cells: a present consensus. Proc Natl Acad Sci U S A (1988) 1.30
Density-dependent modulation of synthesis of keratins 1 and 10 in the human keratinocyte line HACAT and in ras-transfected tumorigenic clones. Differentiation (1989) 1.30
Treatment of erythema multiforme secondary to herpes simplex by prophylactic topical acyclovir. Br Med J (Clin Res Ed) (1981) 1.30
Unmasking a killer: DNA O(6)-methylguanine and the cytotoxicity of methylating agents. Mutat Res (2000) 1.29
Mismatch repair and response to DNA-damaging antitumour therapies. Eur J Cancer (2003) 1.26
Mutations in the hair cortex keratin hHb6 cause the inherited hair disease monilethrix. Nat Genet (1997) 1.25
The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res (1996) 1.25
Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. Nucleic Acids Res (1997) 1.22
Localisation of a gene for Papillon-Lefèvre syndrome to chromosome 11q14-q21 by homozygosity mapping. Hum Genet (1997) 1.21
Prophylactic topical acyclovir for frequent recurrent herpes simplex infection with and without erythema multiforme. Br Med J (Clin Res Ed) (1983) 1.21
A case-control study of the impact of the East Anglian breast screening programme on breast cancer mortality. Br J Cancer (2007) 1.20
Increased risk of skin cancer associated with the presence of epidermodysplasia verruciformis human papillomavirus types in normal skin. Br J Dermatol (2004) 1.20
Cervical spondylotic myelopathy: functional and radiographic long-term outcome after laminectomy and posterior fusion. Neurosurgery (1999) 1.19
Epidermal cytokines and their roles in cutaneous wound healing. Br J Dermatol (1991) 1.19
Generation and characterization of epidermolysis bullosa simplex cell lines: scratch assays show faster migration with disruptive keratin mutations. Br J Dermatol (2003) 1.19
Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer (2010) 1.19
DNA repair. Int Rev Cytol (1981) 1.17
Keratin 15 expression in stratified epithelia: downregulation in activated keratinocytes. J Invest Dermatol (1999) 1.16
Selective binding to DNA base pair mismatches by proteins from human cells. J Biol Chem (1989) 1.16
Mismatch repair defects and O6-methylguanine-DNA methyltransferase expression in acquired resistance to methylating agents in human cells. J Biol Chem (1997) 1.16
Processing in vitro of an abasic site reacted with methoxyamine: a new assay for the detection of abasic sites formed in vivo. Nucleic Acids Res (1991) 1.16
Malignant transformation of cutaneous lesions in renal allograft patients: a role for human papillomavirus. Cancer Res (1993) 1.16